NicOx SA is a France-based biopharmaceutical company engaged in the research, development and future commercialization of investigational drugs for the treatment of inflammatory, cardio metabolic and ophthalmological diseases. It specializes in the nitric oxide-donating technology. The Company�s main products include Naproxcinod, NCX 116 and NCX 6560. Naproxcinod is a nitric oxide-donating compound, which is used in the treatment of signs and symptoms of osteoarthritis. NCX 116 is a nitric oxide-donating prostaglandin F2-alpha analog developed for the potential treatment of glaucoma (a group of eye diseases). NCX 6560 is a nitric oxide-donating derivative which is used to reduce the risk of cardiac events in heart patients. NicOx SA's other products also include nitric oxide-donating NCEs, developed in partnership with Merck & Co and NCX 1047. In December 2013, it acquired Eupharmed.